<DOC>
	<DOCNO>NCT00132093</DOCNO>
	<brief_summary>The purpose study ascertain whether treatment drug eplerenone , take early heart attack , prevents reduce adverse change may otherwise naturally occur within heart muscle , lead ultimately weakening heart muscle premature death .</brief_summary>
	<brief_title>Effects Eplerenone Left Ventricular Remodelling Following Heart Attack</brief_title>
	<detailed_description>Despite advance detection treatment coronary artery disease , numerous campaign promote healthy lifestyle , ischaemic heart disease ( IHD ) remain common worldwide particularly West Scotland . Following heart attack , main pump chamber - left ventricle ( LV ) - significantly damage around 40 % patient extent fails pump effectively . Despite current medical treatment , fail LV slowly continuously deteriorate time ( know LV remodelling ) , lead `` heart failure '' . Eplerenone , hormone blocker ( aldosterone antagonist ) , show reduce death rate improve symptom patient acute heart attack - myocardial infarction ( MI ) - additionally impaired LV function heart failure ( diabetes ) . The researcher assume eplerenone may exert beneficial effect prevent reduce LV remodelling process . Cardiac MRI provide accurate assessment LV function , small number patient require detect difference LV function time compare one group another . The researcher therefore compare sequential cardiac MRI appearance measurement patient acute MI LV impairment baseline ( within 2 week acute MI ) , 3 month 6 month . After first MRI scan , patient assign eplerenone placebo addition usual secondary preventive therapy ( double-blinded ) , continue 6 month , patient 's involvement trial finish . As eplerenone show benefit acute MI plus LV impairment heart failure ( diabetes ) , patient ethically put trial may potentially place placebo group . For reason , slightly different cohort patient use - acute MI LV impairment without clinical heart failure diabetes .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Ventricular Remodeling</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>1 . Age 18 2 . Acute myocardial infarction within last 114 day ( defined typical electrocardiogram [ ECG ] change and/or elevate cardiac enzyme least twice upper limit normal ) 3 . Left ventricular systolic dysfunction ( LVSD ) base echocardiographic wall motion score index ( WMSI ) leave ventricular ejection fraction ( LVEF ) &lt; 40 % 4 . Ability give write informed consent 1 . Clinical radiological heart failure 2 . Established diabetes mellitus 3 . Current use potassium ( K ) spar diuretic , clarithromycin , nefazodone , itraconazole , ketoconazole , ritonavir , nelfinavir , tacrolimus , cyclosporin . 4 . Serum creatinine &gt; 220 µmol/l 5 . Serum potassium &gt; 5.0 mmol/l 6 . Pregnancy 7 . Addison ’ disease 8 . MRIincompatible ( ferrous ) sulphate prosthesis 9 . Claustrophobia ( unable tolerate MR environment ) 10 . Concurrent use phenytoin , carbamazepine , rifampicin St. John ’ Wort ( reduce efficacy eplerenone ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2004</verification_date>
	<keyword>Left ventricular remodelling</keyword>
	<keyword>Acute myocardial infarction</keyword>
	<keyword>Left ventricular dysfunction</keyword>
	<keyword>Eplerenone</keyword>
	<keyword>Cardiac Magnetic Resonance Imaging</keyword>
</DOC>